NCT05905120View on ClinicalTrials.gov

Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

July 26, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

Toludivenlafaxine hydrochloride sustained-release tablets

80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take

Trial Locations (1)

200030

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
collaborator

Yantai University

UNKNOWN

lead

Shanghai Mental Health Center

OTHER